Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMRA (Biomerica) -- Ignore unavailable to you. Want to Upgrade?

To: fossilg who wrote (110)	9/1/1998 5:46:00 PM
From: Leman	Respond to of 170

Tuesday September 1, 8:43 am Eastern Time Company Press Release SOURCE: Biomerica, Inc. Biomerica Introduces New Thyroid Disease Test Worldwide & Seeks U.S. FDA Clearance NEWPORT BEACH, Calif., Sept. 1 /PRNewswire/ -- Biomerica, Inc. (Nasdaq: BMRA - news) announced today that it has filed for clearance with the U.S. Food and Drug Administration to market its new free T4 enzyme immunoassay test. The Company also announced that it has launched its free T4 EIA kit internationally. The estimated worldwide market for all thyroid testing is approximately $600 million. The new non-radioactive enzyme based product determines the amount of free thyroxin (T4) circulating in the bloodstream. This is a significant aid in the assessment of thyroid function. Free T4 is one of the two major thyroid tests used in most clinical situations. The free T4 EIA kit would complete the Company's line of thyroid endocrinology tests. Biomerica currently has five tests to determine thyroid disease and thyroid dysfunction that have been cleared to market by the FDA. Biomerica's new product does not employ radioactivity, thereby simplifying the handling of the test and eliminating radioactive waste. Utilizing a simple microwell format, capable of running 45 patient samples at one time, the new test is easily automated, highly accurate and cost effective. Biomerica's panel of thyroid tests is a key aid to determining the presence of, and monitoring for, Graves' disease, Hashimoto's thyroiditis and primary thyroid failure. Biomerica (Nasdaq: BMRA - news) is a global medical company devoted to developing, manufacturing and marketing advanced medical diagnostic products for the early detection of diseases. The products are used in hospitals, physician's offices and in the home for self testing. Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform act of 1995. Forward-looking statements may involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, the continued demand for the Company's products, availability of raw materials and the state the economy. These and other risks are described in the Company's Annual Report on Form 10-KSB and in the Company's other filings with the Securities and Exchange Commission. SOURCE: Biomerica, Inc.

To: fossilg who wrote (110)	9/1/1998 5:48:00 PM
From: Leman	Read Replies (2) \| Respond to of 170

Thursday August 27, 8:42 am Eastern Time Company Press Release SOURCE: Biomerica, Inc. Biomerica Adds Major Retail Chains For Its Proprietary Colorectal Disease Test NEWPORT BEACH, Calif., Aug. 27 /PRNewswire/ -- Biomerica, Inc. (Nasdaq: BMRA - news) announced today that Ahold USA, a $14 billion company, will distribute the EZ Detect(TM) colorectal disease home test in Ahold pharmacies, Stores owned by Ahold USA include Stop & Shop, Tops Markets, Giant Food Stores, Edwards and Bi-Lo retail chains. Ahold USA owns 817 stores with 464 pharmacies, all of which currently carry a wide range of healthcare products. ''This significantly expands the distribution and availability of EZ Detect in the U.S. which is already being sold at other major chain drug stores such as Walgreens, CVS and Sav-on/Osco,'' said Zackary Irani, Chief Executive Officer. ''Proprietary products such as EZ Detect pave the way for revenue growth for Biomerica and follow our strategy of placing our over-the-counter products in major chain stores worldwide.'' The EZ Detect product is a simple two minute home test to detect occult (hidden) blood in the stool, an early warning sign of colorectal disease including colorectal cancer and diverticulitis. The test is conducted by simply placing the biodegradable test pad in the toilet bowel after a bowel movement. If the test is positive, a blue cross appears on the pad. Unlike other tests, no handling of the stool or dietary restrictions are required. EZ Detect has a suggested retail price of $7.50. The American Cancer Society and American Gastroenterological Society recommend annual testing for colorectal cancer after age 50. Colorectal cancer currently accounts for more than 134,000 new cases ,annually and is the nation's second leading cause of cancer deaths. It is believed that testing for occult blood can be as effective in detecting the early warning signs of colorectal disease as mammograms are for breast cancer detection. There are over 70 million adults over the age of 50 in the U.S. The population in this age group is growing at 2% annually, compared to 1% for overall population. Biomerica (Nasdaq: BMRA - news) is a global medical company devoted to developing, manufacturing and marketing advanced medical diagnostic products for the early detection of diseases. The products are used in hospitals, physician's offices and in the home for self testing. Except for historical information contained herein the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1999. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, the continued demand for the Company's products, availability of raw materials and the state of the economy. These and other risks are described in the Company's Annual Report on Form 10-KSB and in the Company's other filings with the Securities and Exchange Commission.